Activation of phenacetin O-deethylase activity by α-naphthoflavone in human liver microsomes

Xenobiotica

Volumn 29, Issue 9, 1999, Pages 885-898

  Nakajima, M ^a   Kobayashi, K ^b   Oshima, K ^b   Shimada, N ^c   Tokudome, S ^d   Chiba, K ^b   Yokoi, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c DAIICHI PURE CHEMICALS CO LTD   (Japan)

^d Tokyo Medical Examiner's Office   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANILINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; ENZYME ANTIBODY; FLUVOXAMINE; KETOCONAZOLE; LIVER ENZYME; PHENACETIN O DEETHYLASE; RECOMBINANT PROTEIN;

ARTICLE; B LYMPHOBLAST; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER MICROSOME;

ANILINE COMPOUNDS; ARYL HYDROCARBON HYDROXYLASES; B-LYMPHOCYTES; BENZOFLAVONES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; FLUVOXAMINE; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0032828790     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238137     Document Type: Article

References (37)

1. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
2. BOOBIS, A. R., KAHN, G. C., WHYTE, C., BRODIE, M. J. and DAVIS, D. S., 1981, Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochemical Pharmacology, 30, 2451-2456.
3. BOURRIÉ, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321-332.
4. BUTLER, M. A., GUENGERICH, F. P. and KADLUBAR, F. F., 1989, Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4'-methyl-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Research, 49, 25-31.
5. CONNEY, A. H., PANTUCK, E. J., HSIAO, K.-C., GARLAND, W. A., ANDERSON, K. E., ALVARES, A. P. and KAPPAS, A., 1976, Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clinical Pharmacology and Therapeutics, 20, 633-642.
6. GORSKI, J. C., JONES, D. R., WRIGHTON, S. A. and HALL, S. D., 1997, Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica, 27, 243-256.
7. HUANG, M. T., JOHNSON, E. F., MULLER-EBERHARD, U., KOOP, D. R., COON, M. J. and CONNEY, A. H., 1981, Specificity in the activation and inhibition by flavonoids of benzo[a]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes. Journal of Biological Chemistry, 256, 10897-10901.
8. JOHANNESEN, K. A. M. and DEPIERRE, J. W., 1978, Measurement of cytochrome P-450 in the presence of large amounts of contaminating hemoglobin and methemoglobin. Analytical Biochemistry, 86, 725-732.
9. KAHN, G. C., BOOBIS, A. R., BRODIE, M. J., TOVERUD, E. L., MURRAY, S. and DAVIS, D. S., 1985, Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? British Journal of Clinical Pharmacology, 20, 67-76.
10. 5 and cytochrome P-450 and aniline-induced P-450 difference spectrum. Japanese Journal of Pharmacology, 24, 195-203.
11. KOBAYASHI, K., NAKAJIMA, M., CHIBA, K., YAMAMOTO, T., TANI, M., ISHIZAKI, T. and KUROIWA, Y., 1998, Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. British Journal of Clinical Pharmacology, 45, 316-368.
12. KOBAYASHI, K., NAKAJIMA, M., OSHIMA, K., SHIMADA, N., YOKOI, T. and CHIBA, K. Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metabolism and Disposition, in press.
13. KOLEY, A. P., BUTERS, J. T. M., ROBINSON, R. C., MARKOWITZ, A. and FRIEDMAN, F. K., 1997, Differential mechanism of cytochrome P450 inhibition and activation by α-naphthoflavone. Journal of Biological Chemistry, 272, 3149-3152.
14. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
15. MCMANUS, M. E., BURGESS, W. M., VERONESE, M. E., HUGGETT, A., QUATTROCHI, L. C. and TUKEY, R. H., 1990, Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food derived heterocyclic amine mutagens by human cytochrome P450. Cancer Research, 50, 3367-3376.
16. MUCK, W., 1994, Pharmacokinetic drug interaction. In J. Kuhlmann (ed.), Drug Interactions Studies During Drug Development (Munich; W. Zuckschwerdt), pp. 50-54.
17. NAKAJIMA, M., YOKOI, T., MIZUTANI, M., SHIN, S., KADLUBAR, F. F. and KAMATAKI. T., 1994, Phenotyping of CYP1A2 in Japanese population analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiology, Biomarkers & Prevention. 3, 413-421.
18. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily; update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
19. NEWTON, D. J., WANG, R. W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
20. ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
21. PANTUCK, E. J., HSIAO, K.-C., MAGGIO, A., NAKAMURA, K., KUNTZMAN, R. and CONNEY, A. H., 1974, Effect of cigarette smoking on phenacetin metabolism. Clinical Pharmacology and Therapeutics, 15, 9-17.
22. PANTUCK, E. J., PANTUCK, C. B., GARLAND, W. A., MIN, B. H., WATTENBERG, L. W., ANDERSON, K. E., KAPPAS, A. and CONNEY, A. H., 1979, Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clinical Pharmacology and Therapeutics, 25, 88-95.
23. PASTRAKCLJIC, A., TANG, B. K., ROBERTS, E. A. and KALOW, W., 1997, Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Pharmacology, 53, 531-538.
24. RENDIC, S. and DI CARLO, F. J., 1997, Human cytochrome P450 enzymes; a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews, 29, 413-580.
25. RODRIGUES, A. D., 1994, Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochemical Pharmacology, 48, 2147-2156.
26. SCHWAB, G. E., RAUCY, J. L. and JOHNSON, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450 catalyzed steroid hydroxylations by α-naphthoflavone. Molecular Pharmacology, 33, 493-499.
27. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogenes and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
28. SHOU, M., GROGAN. J., MANCEWICZ, J. A., KRAUSZ, W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEWKA, K. R., 1994, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytachrome P450 active site. Biochemistry, 33, 6450-6455.
29. SPATZENEGGER, M. and JAEGER, W., 1995, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 27, 397-417.
30. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINERS, J. O., 1993a, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
31. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., GONZALEZ, F. J. and MINERS, J. O., 1993b, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochemical Pharmacology, 46, 1975-1981.
32. 1 by bacterial recombinant human cytochrome P450 enzymes. Chemical Research in Toxicology, 8, 218-225.
33. UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370-380.
34. WRIGHTON, S. A., CAMPANILE, C., THOMAS, P. E., MAINES, S. L., WATKINS, P. B., PARKER. G., MENDEZ-PICON, G., HANIU, M., SHIVELY, J. E., LEVIN, W. and GUZELIAN, P. S., 1986, Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Molecular Pharmacology, 29, 405-410.
35. 5. Journal of Biological Chemistry, 271, 27438-27444.
36. 5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P4502E1 and by human liver microsomes. Biochemical Pharmacology, 52, 301-309.
37. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Archives of Biochemistry and Biophysics, 325, 174-182.